Impact of lenalidomide on the antiproliferative effect of gemcitabine/carboplatin (GC) and gemcitabine/cisplatin (GP) against urothelial carcinoma (UC) cells in vitro.

e15164 Background:Although urothelial carcinoma (UC) is a chemosensitive malignancy, responses are not durable and most patients with metastatic UC die from their disease. New strategies are needed. Both pre-clinical and clinical data support targeting angiogenesis in UC and other solid tumors. Lenalidomide is an anti-angiogenic and a potent immunomodulatory agent that has demonstrated activity in hematological malignancies. There are no in vitro data of single agent direct activity against solid tumor cells and few data regarding the combination of lenalidomide and standard of care chemotherapeutic agents, such as cisplatin (P), carboplatin (C) and gemcitabine (G). We explored in vitro combinations of lenalidomide, GC and GP to improve possible treatment options for UC. Methods: The effects of lenalidomide alone and in combination with GC or GP, on UC cell proliferation were studied. UC T24 cells were exposed to various concentrations of lenalidomide (0, 0.5uM, 1uM) for 24 hours. This was followed by tre...